Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119191) titled 'T-SAFT (Teprotumumab Safety And efficacy in Chinese TAO patients)' on Feb. 24.

Study Type: Observational study

Study Design: Sequential

Primary Sponsor: Shanghai General Hospital

Condition: thyroid-associated ophthalmopathy

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-02-28

Target Sample Size: TAO observational cohort:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=309249

Published by HT Digital Content Services with permission from Health Daily Digest....